Search

Displaying results 4161 - 4170 of 7284 in total
  1. Drug

    Elamipretide

    go.drugbank.com/drugs/DB11981
    ApprovedInvestigational

    [A274436] Elamipretide is a synthetic tetrapeptide that selectively binds to cardiolipin, a phospholipid in the inner mitochondrial membrane. … Elamipretide is a mitochondrial cardiolipin binder being investigated for diseases involving mitochondrial dysfunction.

  2. Drug

    Kappadione

    go.drugbank.com/drugs/DB09332
    Approved

    Kappadione is a Vitamin K derivative (chemically, it is menadiol sodium diphosphate), previously approved by FDA prior to 1982 and marketed by Lilly Marketing for this drug has been discontinued and is … Studies involving the active metabolite of this formulation, menadione, showed oocyte toxicity in a study of mice [L1544].

  3. Drug

    Sutilain

    go.drugbank.com/drugs/DB09379
    ApprovedWithdrawn

    [T169] Sutilain was developed by Abbott and FDA approved on June 12, 1969. It is currently discontinued.[L2368] … Sutilain contains proteolytic enzymes derived from _Bacillus subtilis_ and it is available as a cream-colored odorless powder.

  4. Drug

    Mivebresib

    go.drugbank.com/drugs/DB21300
    Investigational

    Mivebresib has a monoisotopic molecular weight of 459.11 Da. … Mivebresib is a small molecule drug.

  5. Drug

    Desloratadine

    go.drugbank.com/drugs/DB00967
    ApprovedInvestigational

    Desloratadine is a second generation, tricyclic antihistamine that which has a selective and peripheral H1-antagonist action. … It is the active descarboethoxy metabolite of loratidine (a second generation histamine).

    Mixtures: Clarinex-D 12 Hour, Clarinex-D 24 HourProducts: GLOBISTAMIN D, GLOBISTAMIN D JARABE
  6. Drug

    Bacillus calmette-guerin substrain connaught live antigen

    go.drugbank.com/drugs/DB10804
    ApprovedInvestigationalWithdrawn

    substrain connaught live antigen is intravesically administered for the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary or recurrent stage Ta

  7. Drug

    Hydroxycitronellal

    go.drugbank.com/drugs/DB14187
    Approved

    Sensitivity to hydroxycitronellal may be identified with a clinical patch test. … Hydroxycitronellal has also been shown to be a dermatologic irritant and allergen, and as a result commercially available products are restricted by the International Fragrance Association (IFRA) to contain

  8. Drug

    Isoeugenol

    go.drugbank.com/drugs/DB14188
    Approved

    Allergic reactivity to Isoeugenol may be identified with a patch test. … It is also a significant dermatologic sensitizer and allergen, and as a result has been restricted to 200 p.p.m. since 1998 according to guidelines issued by the fragrance industry [A34278].

  9. Drug

    Cinnamaldehyde

    go.drugbank.com/drugs/DB14184
    Approved

    Sensitivity to cinnamaldehyde may be identified with a clinical patch test. … Cinnamaldehyde is a naturally occurring flavonoid that gives the spice cinnamon its flavour and odour.

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Ravulizumab

    go.drugbank.com/drugs/DB11580
    ApprovedInvestigational

    Ravulizumab is a potent and selective complement 5 (C5) inhibitor. It is a humanized monoclonal IgG2/4 kappa antibody produced in Chinese hamster ovary (CHO) cells. … [A244465] It was later approved by the European Commission on July 2, 2019, for the same indications.[L39710] Ravulizumab is also used to treat myasthenia gravis.